New Diabetes Drug Works Well in Trial

A contest may develop between liraglutide and a once-a-week formulation of exenatide, Buse said. The longer-lasting exenatide version is expected to reach the U.S. market in about a year. It requires a standard hypodermic needle for injection, while liraglutide can be given through a small, ultrafine needle.

Several other GLP-1 drugs are in trials now and might be approved before long, Buse said. "It will be a great opportunity for patients to have so many choices," he added.

More information

Today's oral medications for diabetes are described by the American Diabetes Association.

SOURCES: Alan Garber, M.D., Ph.D., professor, medicine, biochemistry and cell and molecular biology, Baylor College of Medicine, Houston; John Buse, M.D., president, medicine and science, American Diabetes Association, Atlanta; Sten Madsbad, M.D., professor, endocrinology, University of Copenhagen, Denmark; Sept. 25, 2008, The Lancet, online

  • 1
  • |
  • 2
Join the Discussion
You are using an outdated version of Internet Explorer. Please click here to upgrade your browser in order to comment.
blog comments powered by Disqus
You Might Also Like...